Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
INR 208.85
(3.37%)
INR 208.85
(3.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 224.63 Million INR | -15.94% |
| 2022 | 267.21 Million INR | 41.72% |
| 2021 | 188.55 Million INR | 10.53% |
| 2020 | 170.58 Million INR | 116.73% |
| 2019 | 78.7 Million INR | 9.07% |
| 2018 | 72.16 Million INR | 162.47% |
| 2017 | -115.5 Million INR | -197.35% |
| 2016 | 118.64 Million INR | 264.6% |
| 2015 | 32.54 Million INR | 177.88% |
| 2014 | 11.71 Million INR | -44.78% |
| 2013 | 21.2 Million INR | 15.72% |
| 2012 | 18.32 Million INR | -75.42% |
| 2011 | 74.56 Million INR | 3.86% |
| 2010 | 71.79 Million INR | -22.32% |
| 2009 | 92.41 Million INR | 49.73% |
| 2008 | 61.72 Million INR | 100.66% |
| 2007 | 30.76 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 53.29 Million INR | 50.15% |
| 2024 Q2 | 114.59 Million INR | 115.03% |
| 2023 Q1 | 74.79 Million INR | 33.5% |
| 2023 Q2 | 74.72 Million INR | -0.09% |
| 2023 Q3 | 39.63 Million INR | -46.96% |
| 2023 FY | 224.63 Million INR | -15.94% |
| 2023 Q4 | 35.49 Million INR | -10.45% |
| 2022 Q3 | 77.85 Million INR | -25.23% |
| 2022 Q1 | 29.21 Million INR | 11584.0% |
| 2022 FY | 267.21 Million INR | 41.72% |
| 2022 Q4 | 56.02 Million INR | -28.04% |
| 2022 Q2 | 104.12 Million INR | 256.45% |
| 2021 Q4 | 250 Thousand INR | -99.53% |
| 2021 FY | 188.55 Million INR | 10.53% |
| 2021 Q3 | 52.91 Million INR | -19.39% |
| 2021 Q2 | 65.64 Million INR | -4.15% |
| 2021 Q1 | 68.48 Million INR | 34.31% |
| 2020 FY | 170.58 Million INR | 116.73% |
| 2020 Q3 | 54.3 Million INR | 35.46% |
| 2020 Q2 | 40.08 Million INR | 59.06% |
| 2020 Q1 | 25.2 Million INR | 62.1% |
| 2020 Q4 | 50.98 Million INR | -6.1% |
| 2019 Q4 | 15.54 Million INR | -31.9% |
| 2019 FY | 78.7 Million INR | 9.07% |
| 2019 Q1 | 20.03 Million INR | -32.64% |
| 2019 Q3 | 22.83 Million INR | 12.52% |
| 2019 Q2 | 20.29 Million INR | 1.27% |
| 2018 Q1 | 7.27 Million INR | 159.15% |
| 2018 Q2 | 17.69 Million INR | 143.35% |
| 2018 Q3 | 17.44 Million INR | -1.45% |
| 2018 Q4 | 29.74 Million INR | 70.53% |
| 2018 FY | 72.16 Million INR | 162.47% |
| 2017 Q1 | -42.2 Million INR | -617.37% |
| 2017 Q4 | -12.29 Million INR | 45.28% |
| 2017 Q3 | -22.47 Million INR | 41.69% |
| 2017 Q2 | -38.53 Million INR | 8.7% |
| 2017 FY | -115.5 Million INR | -197.35% |
| 2016 Q1 | 6.41 Million INR | -67.95% |
| 2016 FY | 118.64 Million INR | 264.6% |
| 2016 Q2 | 5.03 Million INR | -21.53% |
| 2016 Q3 | 99.04 Million INR | 1867.85% |
| 2016 Q4 | 8.15 Million INR | -91.76% |
| 2015 FY | 32.54 Million INR | 177.88% |
| 2015 Q4 | 20.01 Million INR | 473.22% |
| 2015 Q3 | 3.49 Million INR | -20.57% |
| 2015 Q2 | 4.39 Million INR | -5.59% |
| 2015 Q1 | 4.65 Million INR | 585.57% |
| 2014 Q3 | 262 Thousand INR | -92.86% |
| 2014 Q2 | 3.67 Million INR | -48.27% |
| 2014 Q1 | 7.09 Million INR | -41.91% |
| 2014 FY | 11.71 Million INR | -44.78% |
| 2014 Q4 | 679 Thousand INR | 159.16% |
| 2013 Q1 | 36 Thousand INR | -98.9% |
| 2013 Q2 | 59 Thousand INR | 63.89% |
| 2013 Q4 | 12.22 Million INR | 37.43% |
| 2013 Q3 | 8.89 Million INR | 14971.19% |
| 2013 FY | 21.2 Million INR | 15.72% |
| 2012 Q1 | 6000.00 INR | -99.94% |
| 2012 Q2 | 4.19 Million INR | 69800.0% |
| 2012 Q3 | 10.84 Million INR | 158.46% |
| 2012 Q4 | 3.28 Million INR | -69.68% |
| 2012 FY | 18.32 Million INR | -75.42% |
| 2011 FY | 74.56 Million INR | 3.86% |
| 2011 Q3 | 23.22 Million INR | -8.57% |
| 2011 Q2 | 25.4 Million INR | 0.0% |
| 2011 Q4 | 9.4 Million INR | -59.51% |
| 2010 FY | 71.79 Million INR | -22.32% |
| 2009 FY | 92.41 Million INR | 49.73% |
| 2008 FY | 61.72 Million INR | 100.66% |
| 2007 FY | 30.76 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 96.352% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 99.292% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 95.23% |
| Granules India Limited | 4.05 Billion INR | 94.458% |
| Indoco Remedies Limited | 984.6 Million INR | 77.186% |
| Achyut Healthcare Limited | 5.73 Million INR | -3818.876% |
| Ajanta Pharma Limited | 8.16 Billion INR | 97.248% |
| Alkem Laboratories Limited | 17.95 Billion INR | 98.749% |
| Alpa Laboratories Limited | 167.76 Million INR | -33.896% |
| Brooks Laboratories Limited | -195.91 Million INR | 214.655% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 86.092% |
| Bajaj HealthCare Limited | -837.93 Million INR | 126.808% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 70.23% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.597% |
| Eris Lifesciences Limited | 3.91 Billion INR | 94.269% |
| FDC Limited | 3.05 Billion INR | 92.64% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 101.496% |
| Gufic Biosciences Limited | 861.35 Million INR | 73.921% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 94.664% |
| Ipca Laboratories Limited | 5.47 Billion INR | 95.896% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 213.861% |
| Lasa Supergenerics Limited | -217.3 Million INR | 203.37% |
| Laurus Labs Limited | 1.6 Billion INR | 86.009% |
| Lupin Limited | 19.14 Billion INR | 98.827% |
| Mankind Pharma Limited | 19.12 Billion INR | 98.826% |
| Medicamen Biotech Limited | 109.31 Million INR | -105.498% |
| Medico Remedies Limited | 82.9 Million INR | -170.936% |
| Megasoft Limited | -127.46 Million INR | 276.227% |
| NATCO Pharma Limited | 13.88 Billion INR | 98.382% |
| Piramal Pharma Limited | 178.2 Million INR | -26.055% |
| RPG Life Sciences Limited | 876.6 Million INR | 74.375% |
| Sigachi Industries Limited | 571.8 Million INR | 60.715% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.765% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 92.519% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 11.263% |
| Unichem Laboratories Limited | -704.74 Million INR | 131.874% |
| Wanbury Limited | 559.56 Million INR | 59.856% |
| Windlas Biotech Limited | 581.87 Million INR | 61.395% |
| ZIM Laboratories Limited | 172.46 Million INR | -30.247% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.418% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 105.801% |
| Divi's Laboratories Limited | 16 Billion INR | 98.596% |
| Hester Biosciences Limited | 188.89 Million INR | -18.921% |
| Procter & Gamble Health Limited | 2 Billion INR | 88.823% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 50.052% |
| Bal Pharma Limited | 73.92 Million INR | -203.874% |
| Strides Pharma Science Limited | -706.14 Million INR | 131.811% |
| Venus Remedies Limited | 284.9 Million INR | 21.157% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 89.644% |
| Nectar Lifesciences Limited | 49.95 Million INR | -349.71% |
| Shilpa Medicare Limited | 318.74 Million INR | 29.526% |
| Aarti Drugs Limited | 1.71 Billion INR | 86.896% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 83.29% |
| Suven Life Sciences Limited | -1.05 Billion INR | 121.378% |
| Ind-Swift Limited | 142.31 Million INR | -57.842% |
| Valiant Laboratories Limited | 3.19 Million INR | -6928.473% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 95.935% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 103.959% |
| Themis Medicare Limited | 435.23 Million INR | 48.389% |
| Hikal Limited | 696.02 Million INR | 67.727% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 98.644% |
| Sequent Scientific Limited | -358.69 Million INR | 162.625% |
| Novartis India Limited | 851.9 Million INR | 73.632% |
| Wockhardt Limited | -4.63 Billion INR | 104.852% |
| Jubilant Pharmova Limited | 771 Million INR | 70.865% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -3067.372% |
| Neuland Laboratories Limited | 3 Billion INR | 92.514% |
| Morepen Laboratories Limited | 961.59 Million INR | 76.64% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -53.841% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 347.616% |